Ocular Therapeutix

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Ocular Therapeutix 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. 

CEO
Pravin U. Dugel
CEOPravin U. Dugel
Employees
325
Employees325
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
2006
Founded2006
Employees
325
Employees325

OCUL Key Statistics

Market cap
1.81B
Market cap1.81B
Price-Earnings ratio
-5.89
Price-Earnings ratio-5.89
Dividend yield
Dividend yield
Average volume
3.58M
Average volume3.58M
High today
$8.75
High today$8.75
Low today
$8.24
Low today$8.24
Open price
$8.68
Open price$8.68
Volume
3.35M
Volume3.35M
52 Week high
$16.44
52 Week high$16.44
52 Week low
$5.80
52 Week low$5.80

Stock Snapshot

The current Ocular Therapeutix(OCUL) stock price is $8.30, with a market capitalization of 1.81B. The stock trades at a price-to-earnings (P/E) ratio of -5.89.

As of 2026-04-01, Ocular Therapeutix(OCUL) stock has fluctuated between $8.24 and $8.75. The current price stands at $8.30, placing the stock +0.8% above today's low and -5.1% off the high.

The Ocular Therapeutix(OCUL)'s current trading volume is 3.35M, compared to an average daily volume of 3.58M.

In the last year, Ocular Therapeutix(OCUL) shares hit a 52-week high of $16.44 and a 52-week low of $5.80.

In the last year, Ocular Therapeutix(OCUL) shares hit a 52-week high of $16.44 and a 52-week low of $5.80.

OCUL News

Simply Wall St 4d
Why Ocular Therapeutix Is Down 7.7% After Single‑Trial FDA Plan For AXPAXLI Superiority Claim

Earlier this year, Ocular Therapeutix reported that its Phase 3 SOL-1 trial for AXPAXLI in retinal disease met its primary endpoint, showing superiority to EYLE...

Why Ocular Therapeutix Is Down 7.7% After Single‑Trial FDA Plan For AXPAXLI Superiority Claim

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own OCUL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.